179 related articles for article (PubMed ID: 32228342)
21. Association between abnormal gastric function risk and Helicobacter pylori infection assessed by ELISA and 14C-urea breath test.
Gong Y; Wei W; Yuan Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):316-20. PubMed ID: 25284372
[TBL] [Abstract][Full Text] [Related]
22. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.
Al-Assi MT; Miki K; Walsh JH; Graham DP; Asaka M; Graham DY
Am J Gastroenterol; 1999 Sep; 94(9):2367-72. PubMed ID: 10483993
[TBL] [Abstract][Full Text] [Related]
24. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti- CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran.
Mansour-Ghanaei F; Joukar F; Rajpout Y; Hasandokht T
Asian Pac J Cancer Prev; 2014; 15(18):7635-8. PubMed ID: 25292040
[TBL] [Abstract][Full Text] [Related]
25. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.
Shikata K; Ninomiya T; Yonemoto K; Ikeda F; Hata J; Doi Y; Fukuhara M; Matsumoto T; Iida M; Kitazono T; Kiyohara Y
Scand J Gastroenterol; 2012 Jun; 47(6):669-75. PubMed ID: 22428879
[TBL] [Abstract][Full Text] [Related]
26. Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17.
Goni E; Venerito M; Schulz C; Weigt J; Langner C; Link A; Malfertheiner P
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1340-1345. PubMed ID: 28984679
[TBL] [Abstract][Full Text] [Related]
27. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
[TBL] [Abstract][Full Text] [Related]
28. Serum gastrin level and pepsinogen I/II ratio as biomarker of Helicobacter pylori chronic gastritis.
Arinton IG
Acta Med Indones; 2010 Jul; 42(3):142-6. PubMed ID: 20724767
[TBL] [Abstract][Full Text] [Related]
29. Histologic and serum risk markers for noncardia early gastric cancer.
Shiotani A; Iishi H; Uedo N; Kumamoto M; Nakae Y; Ishiguro S; Tatsuta M; Graham DY
Int J Cancer; 2005 Jun; 115(3):463-9. PubMed ID: 15688378
[TBL] [Abstract][Full Text] [Related]
30. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of two serological methods in screening gastric cancer and its precancerous condition].
Li MY; Zhang DQ; Lu X; Chen WC
Zhonghua Nei Ke Za Zhi; 2018 Dec; 57(12):907-911. PubMed ID: 30486559
[No Abstract] [Full Text] [Related]
32. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population.
Miki K; Fujishiro M; Kodashima S; Yahagi N
Dig Endosc; 2009 Apr; 21(2):78-81. PubMed ID: 19691778
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of pepsinogen I, pepsinogen II, and gastrin-17 in the course of Helicobacter pylori gastritis in pediatrics.
Kalach N; Legoedec J; Wann AR; Bergeret M; Dupont C; Raymond J
J Pediatr Gastroenterol Nutr; 2004 Nov; 39(5):568-9. PubMed ID: 15572903
[No Abstract] [Full Text] [Related]
35. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology.
Leja M; Kupcinskas L; Funka K; Sudraba A; Jonaitis L; Ivanauskas A; Janciauskas D; Kiudelis G; Chiu HM; Lin JT
Dig Dis Sci; 2009 Nov; 54(11):2377-84. PubMed ID: 19731026
[TBL] [Abstract][Full Text] [Related]
36. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
37. Changes with aging in gastric biomarkers levels and in biochemical factors associated with
Shan JH; Bai XJ; Han LL; Yuan Y; Sun XF
World J Gastroenterol; 2017 Aug; 23(32):5945-5953. PubMed ID: 28932086
[TBL] [Abstract][Full Text] [Related]
38. Gastric cancer screening using the serum pepsinogen test method.
Miki K
Gastric Cancer; 2006; 9(4):245-53. PubMed ID: 17235625
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
Gong YH; Sun LP; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
[TBL] [Abstract][Full Text] [Related]
40. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
Germaná B; Di Mario F; Cavallaro LG; Moussa AM; Lecis P; Liatoupolou S; Comparato G; Carloni C; Bertiato G; Battiestel M; Papa N; Aragona G; Cavestro GM; Iori V; Merli R; Bertolini S; Caruana P; Franzé A
Dig Liver Dis; 2005 Jul; 37(7):501-8. PubMed ID: 15975537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
